Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF

Journal of the American Society of Nephrology

Volumn 10, Issue 8, 1999, Pages 1700-1708

  Cheung, Po Kam ^c   Stulp, Ben ^c   Immenschuh, Stephan ^a   Borghuis, Theo ^c   Baller, Julius F W ^c   Bakker, Winston W ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEMOPEXIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PLASMA PROTEIN; POLYCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; ARTICLE; DOT HYBRIDIZATION; ENZYME INHIBITION; GLOMERULUS FILTRATION; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LYMPHATIC SYSTEM TUMOR; NEPHROTIC SYNDROME; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RELAPSE; REMISSION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

EID: 0013646663     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Savin VJ: Mechanisms of proteinuria in noninflammatory glomerular diseases. Am J Kidney Dis 21: 347-362, 1993
2. Schnaper HW, Robson AM: Nephrotic syndrome: Minimal change disease, focal glomerulosclerosis and related disorders. In: Diseases of the Kidney, 5th Ed., edited by Schrier RW, Gottschalk CW, Boston, Little, Brown & Co, 1993, pp 1731-1785
3. Barratt M, Clark G: Minimal change nephrotic syndrome and focal segmental glomerulosclerosis. In: Pedriatic Nephrology, 3rd Ed., edited by Holliday MA, Barratt TM, Avner ED, Baltimore, Williams & Wilkins, 1994, pp 767-787
4. Tapie J, Laporte J, Richalens J: Syndrome nephrotique au cours de a maladie de Hodgkin-Sternberg. Presse Med 65: 287-289, 1957
5. Belghiti D, Vernat J, Hiec G, Gubler M, Andre C, Sobel A: Nephrotic syndrome associated with T cell lymphoma. Cancer 47: 1878-1882, 1981
6. Morel-Maroger-Striker L, Striker GE: Glomerular lesions in malignancies. Contrib Nephrol 48: 111-124, 1985
7. Shaloub RJ: Pathogenesis of lipoid nephŕosis: A disorder of T-cell function. Lancet 2: 556-559, 1974
8. Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B: A vascular permeability factor elaborated from lymphocytes: Demonstration in patients with nephrotic syndrome. Biomedicine 23: 37-49, 1975
9. Bakker WW, Beukhof JR, van Luijk WHJ, van der Hem GK: Vascular permeability increasing factor (VPF) in IgA nephropathy. Clin Nephrol 18: 165-167, 1982
10. Boulton-Jones JM, Tulloch J, Dore B, McKay A: Changes in the capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 20: 72-76, 1983
11. Schnaper HW, Pierce CW, Aune TM: Identification and initial characterization of concanavalin A and interferon-induced human suppressor factors: Evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J Immunol 132: 2429-2435, 1984
12. Tomizawa S, Maruyama K, Nagasawa N, Suzuki S, Kurome T: Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome. Nephron 41: 157-160, 1985
13. Wilkinson A, Williams DG, Gillespie C, Hartley B: Nephrotic plasma increases proteinuria and reduced anionic sites on the glomerular basement membrane in vivo in NZW rabbits [Abstract]. Kidney Int 29: 295, 1986
14. Heslan JM, Branellec A, Laurent J, Lagrue G: The vascular permeability factor in a T lymphocyte product. Nephron 42: 187-188, 1986
15. Levin M, Gascione P, Turner MW, Barratt TM: A highly cationic protein in the plasma and urine of children with steroid-responsive nephrotic syndrome. Kidney Int 36: 867-877, 1989
16. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40: 453-460, 1991
17. Thomson NM, Kraft N: Normal human serum contains the lymphotoxin found in minimal change nephropathy. Kidney Int 31: 1186-1193, 1987
18. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jaques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soullilou JP: Effect of plasma protein absorption on protein excretion in kidney transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330: 7-14, 1994
19. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334: 878-883, 1996
20. Bakker WW, Baller JFW, van Luijk WHJ: A kallikrein-like molecule and plasma vasoactivity in minimal change disease. Contrib Nephrol 67: 31-36, 1988
21. Cheung PK, Boes A, Dijkhuis FWJ, Klok PA, Bakker WW: Enhanced glomerular permeability and minimal change disease like alterations of the rat kidney induced by a vasoactive human plasma factor [Abstract]. Kidney Int 47: 1218, 1995
22. Cheung PK, Klok PA, Bakker WW: Minimal change-like glomerular alterations induced by a human plasma factor. Nephron 74: 586-593, 1996
23. Cheung PK, Klok PA, Bakker WW: Induction of experimental proteinuria in vivo following infusion of a human plasma factor associated with minimal change disease. Kidney Int 52: 562, 1997
24. Hrkal Z, Kuzelová K, Muller-Eberhard U, Stern R: Hyaluronan binding properties of human serum hemopexin. FEBS Lett 383: 72-74, 1996
25. Hewick RM, Hunkapiller MW, Hood LE, Dreyer WJ: A gas-liquid solid phase peptide and protein sequenator. J Biol Chem 256: 7990-7997, 1981
26. Muller-Eberhard U: Hemopexin. Methods Enzymol 163: 535-565, 1988
27. Mohos SC, Skoza L: Histochemical demonstration and localization of sialoproteins in the glomerulus. Exp Mol Pathol 12: 316-323, 1971
28. Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW: Intraglomerular platelet aggregation and experimental glomerulonephritis. Kidney Int 37: 1500-1508, 1990
29. Hoyer JR, Mauer SM, Michael AF: Unilateral renal disease in the rat. I. Clinical, morphological, and glomerular mesangial functional features for the experimental model produced by renal perfusion with aminonucleoside. J Lab Clin Med 85: 756-768, 1975
30. Moser TL, Enghild JJ, Pizzo SV, Stack MS: Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J 307: 867-873, 1995
31. Liang OD, Preissner KT, Chhatwal GS: The hemopexin-type repeats of human vitronectin are recognized by Streptococcus pyogenes. Biochem Biophys Res Commun 234: 445-449, 1997
32. Kuzelova K, Mrhalova M, Hrkal Z: Kinetics of heme interaction with heme-binding proteins: The effect of heme aggregation state. Biochem Biophys Acta 1336: 497-501, 1997
33. Vincent SH, Grady RW, Shaklai N, Snider JM, Muller-Eberhard U: The influence of heme-binding proteins in heme-catalyzed oxidations. Arch Biochem Biophys 265: 539-550, 1988
34. Zhu L, Hope TJ, Hall J, Davies A, Stern M, Muller-Eberhard U, Stern R, Parslow TG: Molecular cloning of a mammalian hyaluronidase reveals identity with hemopexin, a serum heme-binding protein. J Biol Chem 269: 32092-32097, 1994
35. Cheung PK, van Luijk WHJ, Nauta J, Borghuis T, Bakker WW: The vasoactive plasma factor 100KF and minimal change disease [Abstract]. J Am Soc Nephrol 9: 85A, 1998
36. Blau EB, Haas JE: Glomerular sialic acid and proteinuria in human renal disease. Lab Invest 38: 477-482, 1973
37. Cheung PK, Baller JEW, van der Horst, Bakker WW: Expression of glomerular ecto-ATPase in idiopathic nephrotic syndrome. In: Ecto-ATPases: Recent Progress on Structure and Function, edited by Plesner L, Kirley TL, Knowles F, New York, Plenum, 1996, pp 187-197